Literature DB >> 10877989

Maternal outcome following temporizing management of the (H)ELLP syndrome.

M G van Pampus1, H Wolf, A Ilsen, P E Treffers.   

Abstract

OBJECTIVE: The aim of the study was to describe the clinical progress and maternal outcome of the (H)ELLP syndrome following temporizing management.
METHODS: All women (n = 127) admitted in the Academic Medical Center in Amsterdam between 1984 and 1996 with (H)ELLP syndrome and a live fetus in utero were included. The patients were treated by temporizing management, including the use of antihypertensives and magnesium sulfate. The predominant indication for terminating pregnancy was fetal distress or fetal death, and not maternal condition. MAIN OUTCOME MEASURES: Maternal mortality and morbidity.
RESULTS: All serious maternal complications occurred at the onset of the syndrome. Two mothers with HELLP syndrome died following a cerebral hemorrhage. The remaining patients recovered completely. Serious maternal morbidity occurred more often in cases of HELLP than in cases of ELLP syndrome. Seventy-nine (62%) women were not delivered after 3 days and 65 (51%) after 7 days.
CONCLUSIONS: Severe complications only occurred at the onset of (H)ELLP syndrome. It is unlikely that a more aggressive approach would have reduced maternal mortality or morbidity.

Entities:  

Mesh:

Year:  2000        PMID: 10877989     DOI: 10.1081/prg-100100137

Source DB:  PubMed          Journal:  Hypertens Pregnancy        ISSN: 1064-1955            Impact factor:   2.108


  2 in total

1.  Comparison of maternal and neonatal outcomes in women with HELLP syndrome and women with severe preeclampsia without HELLP syndrome.

Authors:  Abdulkadir Turgut; Oya Demirci; Elif Demirci; Mehmet Uludoğan
Journal:  J Prenat Med       Date:  2010-07

2.  Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction.

Authors:  Bhavisha A Bakrania; Frank T Spradley; Heather A Drummond; Babbette LaMarca; Michael J Ryan; Joey P Granger
Journal:  Compr Physiol       Date:  2020-12-09       Impact factor: 9.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.